Independent research in a $50B market.
GLP-1 Picks exists because the telehealth GLP-1 market is loud, confusing, and full of paid recommendations dressed up as reviews. We rank 40 providers by a fixed methodology — and we publish how we do it.
Our Mission
Help the millions of Americans navigating GLP-1 medications find a program that fits their budget, clinical needs, and safety standards — without hidden fees, intro-rate bait, or provider-paid placement.
The GLP-1 market is projected to hit $133B by 2035. That much money attracts a lot of bad actors. Our job is to tell you which providers are worth your money and which are not, using the same methodology for all 40.
How we're different
No pay-for-placement
Providers cannot pay to rank higher. Our scoring is based on a fixed, published methodology: pricing (25%), clinical oversight (25%), medication options (20%), user experience (15%), transparency (15%). Affiliate partnerships exist — we disclose them openly — but they do not influence editorial rankings. Where our editorial judgment aligns with an affiliate partner, that's because the provider earned the ranking, not because they paid for it.
Prices we verify ourselves
Every price shown on this site was checked against the provider's live website in the last 30 days. No cached pricing, no pre-promotion intro rates, no "starting at" numbers that jump 2-3x after month one. If a provider changes their pricing, we update our ranking the same week.
Independent, not a pharma front
We don't take money from drug manufacturers, pharmacies, or compounding labs. We don't run sponsored content. Our only revenue is affiliate commissions when a reader chooses a provider we recommend and signs up. That means our incentive aligns with yours: recommend good providers so you actually use them, not ones who paid the most.
What we cover
40 telehealth providers
Independent reviews of every major GLP-1 telehealth platform, with scores, pricing, pros/cons, and detailed analysis.
780 provider comparisons
Side-by-side comparisons of every provider pair — pricing, medications, clinical oversight, insurance.
All 50 states + DC
Medicaid coverage, regulatory landscape, and top providers for every state.
FDA safety tracking
Active monitoring of FDA warning letters, compounding enforcement, and provider safety flags.
Pipeline drugs
Retatrutide, orforglipron, Foundayo, and what's coming next — with source-cited timelines.
Medicare GLP-1 Bridge
Eligibility, pricing, and prep for the July 2026 Medicare Part D launch.
Editorial principles
Who's behind GLP-1 Picks
Iacob Pastina
Independent technology researcher and publisher. Builds comparison sites through methodical research across pricing, clinical oversight, regulatory signals, and user outcomes. Not a medical professional — every clinical claim on this site links to primary sources (NEJM, FDA, CMS, manufacturer trial data).
Iacob personally verifies every provider ranking and writes or edits every article on the site. GLP-1 Picks is independently operated — no investors, no pharmaceutical or telehealth parent company.
Get in touch
Tips, corrections, or errors in our data: editor@glp1picks.com. We take corrections seriously — if we got a price wrong, a score wrong, or misstated a clinical fact, we want to know.
Provider partnerships:We review every provider on the same methodology regardless of partnership status. If you're a provider interested in an affiliate partnership, email the same address.
Press & media: Same inbox. We respond to every email from a verified journalist within 2 business days.
Reader questions: For help choosing a provider, the match quizis faster than email. If you've used it and still want a human opinion, the inbox is open.